What We're Reading: Page 124
Industry reads hand-picked by our editors
Mar 01, 2022
Feb 28, 2022
Feb 25, 2022
-
Endpoints News
For biotech, Russian invasion of Ukraine threatens to upend a slew of early-stage R&D projects
-
The Financial Times
Short on South Korea biotech company turns into $1bn trader nightmare
-
Bloomberg
How to Repair the Pandemic’s Damage to Cancer Care
-
Science
Largest bacterium ever discovered has an unexpectedly complex cell
Feb 24, 2022
-
The Wall Street Journal
Medicare Proposal on Alzheimer’s Drug Draws Criticism From Drugmakers
-
Reuters
U.S. FDA limits use of GlaxoSmithKline-Vir COVID-19 drug
-
FiercePharma
'Major blunder:' Ex-staffers blast Bristol Myers Squibb's handling of Breyanzi approval in latest CVR lawsuit update
-
MIT Technology Review
The US government is ending the China Initiative. Now what?
Feb 23, 2022
Feb 22, 2022
-
Endpoints News
Biopharma has hyped AI for years. But as the first trials get underway, experts try to manage expectations
-
The New York Times
Got a Covid Booster? You Probably Won't Need Another for a Long Time
-
FiercePharma
Roche settles lawsuit claiming AstraZeneca's Ultomiris infringes delivery patent
-
The Boston Globe
Dr. Paul Farmer, who tirelessly brought health care to the world’s neediest, dies at 62
Feb 18, 2022
-
The Wall Street Journal
Lower Omicron Efficacy Delayed FDA Review on Pfizer Shot in Kids Under 5
-
Endpoints News
Amgen quietly kills an obesity program, casting bleak future for once-promising target
-
Generics Bulletin
Revlimid Rivals Launch Across Europe
Previous
